Navigation Links
New First-of-Its-Kind Study Shows Growing Share of Medicine List Prices Going to Rebates and Supply Chain
Date:1/18/2017

WASHINGTON, Jan. 18, 2017 /PRNewswire-USNewswire/ --  Robust competition in the private marketplace is resulting in increasingly higher rebates and discounts on medicine prices, according to a new study by the Berkeley Research Group (BRG). The study is among the first to examine the share of prescription medicine spending retained by biopharmaceutical companies, generic manufacturers, pharmacy benefit managers (PBMs), health plans and other stakeholders in the supply chain.

"The BRG study is the first to show what happens when the list price of a medicine meets the forces of private market negotiation, costs associated with a complex supply chain and mandated government discounts in Medicaid, the VA and the 340B program," said Stephen J. Ubl, president and chief executive officer of the Pharmaceutical Research and Manufacturers of America, or PhRMA, the organization that commissioned the study.

According to the BRG report, brand biopharmaceutical companies retained just $219 billion, or 63 percent, of total gross (based on list price) spending on brand medicines. This finding suggests, on average, more than a third of the list price of a brand prescription medicine is rebated back to PBMs, health plans and the government, or retained by other stakeholders in the biopharmaceutical supply chain.

The analysis also found that the share of gross (based on list price) spending on medicines that brand biopharmaceutical companies retain has been declining as retrospective rebates, discounts and fees have increased from an estimated $67 billion in 2013 to $106 billion in 2015. Payers are increasingly demanding higher rebates to stay on formulary at the same time that there has been an increase in mandatory rebates in Medicaid and the rapidly growing 340B program.

"The study begs an important question: Are we doing enough to ensure the growing amount of rebates and discounts flow to the patient?" said Ubl, noting that unlike care received at an in-network hospital or physician's office, a patient's cost-sharing for medicines, including payments for care received prior to meeting a deductible or from a co-insurance, is typically based on the list price of a medicine, not the net prices after rebates and discounts are factored in.

In addition to robust competition and negotiation from payers, brand medicines also face competition from generic alternatives, which currently account for 90 percent of all medicines received by patients. After accounting for discounts and rebates, the BRG report estimates that brand biopharmaceutical companies realized less than half (47 percent) of total U.S. spending on prescription drugs in 2015.

Last year, PhRMA outlined a series of policy proposals to improve the competitive market and enable the private sector to lead the move to a more value-driven health care system. "Our health care system needs to evolve to pay for medicines based on their value to patients, the health care system and society," Ubl said.

View the full BRG study here and an executive summary here.

About PhRMA
The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country's leading innovative biopharmaceutical research companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier and more productive lives. Since 2000, PhRMA member companies have invested more than half a trillion dollars in the search for new treatments and cures, including an estimated $58.8 billion in 2015 alone.

Connect with PhRMA
For information on how innovative medicines save lives, please visit:
www.PhRMA.org
www.FromHopetoCures.org
www.Facebook.com/PhRMA
www.Twitter.com/PhRMA

Contact: Holly Campbell
                202-835-3460

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/new-first-of-its-kind-study-shows-growing-share-of-medicine-list-prices-going-to-rebates-and-supply-chain-300392611.html


'/>"/>
SOURCE Pharmaceutical Research and Manufacturers of America (PhRMA)
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. The Breast Cancer Research Foundation Launches First-of-Its-Kind Breast Cancer Clinical Research Funding Model
2. Parenteral Drug Association Publishes First-of-its-Kind Comparison of Sterile Processing GMPs
3. University Of Maryland School Of Medicine Researchers to Begin Clinical Trial Of GammaPod, A First-Of-Its-Kind Radiation Therapy System To Treat Early Breast Cancers
4. RBELL Medical Introduces The CleoPen, A First-of-its-kind Aesthetic Tool for Natural Collagen Induction Therapy
5. Valencia Technologies Issued Two Additional U.S. Patents for First-of-its-Kind Platform Technology
6. Geneia Launches First-of-its-Kind Partnership to Use Advanced Analytics to Improve the Quality and Cost of Care for Skilled Nursing and Rehabilitation Patients
7. Zebra Technologies Expands Healthcare Solution Offering and Introduces First-of-its-Kind Desktop Printer for Sterile Environments
8. Reminder/Media Advisory/AFFiRiS AG Presents Early Clinical Data on a First-of-its-Kind Parkinsons Disease Vaccine
9. Janssen, the Pharmaceutical Companies of Johnson & Johnson, Announces First-of-its-Kind Drug Donation Program for HIV Treatment-Experienced Children
10. Philips launches new EPIQ premium ultrasound system with first-of-its-kind nSIGHT technology and Anatomical Intelligence, to address complicated imaging needs of an aging global population
11. Global Market Study on Precision Medicine: Drug Discovery Technology Segment Estimated to Witness 0.1% Decline in Market Share Between 2016 and 2024
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2019)... ... June 24, 2019 , ... A new report ... laboratory information management system, or LIMS. , Not only that, an estimated 44% ... a new report, " The 2019 Market for Laboratory Software LIMS, CDS, MSS ...
(Date:6/24/2019)... ... June 24, 2019 , ... ... Boston, Massachusetts-based digital experience agency, is pleased to announce that its annual ... a Communicator Award of Excellence https://www.communicatorawards.com/winners/list/?event=1026&category=1915&award=8 in the Collateral category ...
(Date:6/20/2019)... ... June 20, 2019 , ... ... Treatment Centers Columbus East, its first opioid treatment program (OTP) in Ohio ... clinic, located at 1805 E. Main Street, Columbus, is now accepting patients. ...
Breaking Medicine Technology:
(Date:6/20/2019)... ... June 20, 2019 , ... ... and IT services, announced that Angel Rosa has been appointed as Senior Vice ... in developing and implementing new services, growing and nurturing high performing teams, and ...
(Date:6/20/2019)... OKLAHOMA CITY, Okla. (PRWEB) , ... June 20, ... ... provider, is pleased to announce their partnership with Physical Therapy Solutions in Lawton, ... Street, Suite C, the clinic is the group’s 28th clinic in the state. ...
(Date:6/19/2019)... ... June 19, 2019 , ... ... institutions, media, and government joined Global Health Council (GHC) and Global Water ... access to water, sanitation, and hygiene (WASH) in healthcare facilities. , ...
(Date:6/19/2019)... ... , ... CEO Steven C. Bilt of Smile Brands Inc. has won a ... Glassdoor , one of the world’s largest job and recruiting sites, released its annual ... countries throughout North America and parts of Europe. , Smile Brands, a leading dental ...
(Date:6/19/2019)... (PRWEB) , ... June 19, 2019 , ... A ... in the United States, has filed class action lawsuits in 34 of the ... defendants in the class actions are an array of pharmaceutical manufacturers, distributors and retailers, ...
Breaking Medicine News(10 mins):